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ErbB receptors and tetraspanins: casting the net wider. 
 
Fedor Berditchevski and Elena Odintsova 
Institute of Cancer and Genomic Sciences, University of Birmingham, 
Edgbaston, Birmingham, UK, B15 2TT  
 
Two decades ago it was first proposed that four transmembrane domain 
proteins of the tetraspanin superfamily function as membrane adaptors (or 
facilitators) for protein interactions (1; 2). Ever since, researchers have been 
trying to find a common ground which would explain how these small proteins 
affect so many seemingly unrelated processes such as cell-cell fusion, 
antigen presentation and receptor mediated signal transduction. Up until 
recently, the widely held view was that tetraspanins connect various protein 
assemblies on the membrane thus forming an interlinked network of functional 
hubs often referred to as tetraspanin-enriched microdomains or tetraspanin 
webs (3). However, the idea of tetraspanin-based networks has been recently 
challenged in the report which demonstrated, using super resolution 
microscopy, that various tetraspanins are localized in separate, mostly non-
overlapping nanoclusters (4). Whilst this observation may pave the way for 
the reassessment of a more general model of tetraspanin microdomain 
organisation, the conceptual view of tetraspanins as regulators of 
compartmentalization and clustering of the associated receptors remains the 
main investigative theme. 
In this short review we will specifically focus on the links between tetraspanin 
proteins and ErbB receptors (Fig.1). For a more general overview of how 
various types of membrane microdomains regulate activities of receptor 
tyrosine kinases readers are referred to an excellent recent review article by 
Delos Santos and colleagues (5). 
 
ErbB receptors 
ErbB receptors are four monomeric receptor tyrosine kinases (i.e. 
EGFR/ErbB1, ErbB2/Her2, ErbB3 and ErbB4), which are activated by soluble 
and membrane-bound EGF ligands. Ligand binding induces homo- and 
heterodimerization of the receptors leading to phosphorylation of their 
cytoplasmic regions at multiple tyrosine residues, assembly of a variety 
signalling complexes and activation of signalling networks that control cell 
proliferation, migration, survival and differentiation (6). Signalling via ErbB 
proteins is controlled at various levels including such steps as the receptor 
clustering, post-endocytic trafficking  and sorting, and lysosomal degradation. 
Post-biosynthetic trafficking and proteolytic-based maturation of EGF ligands 
diversify the ErbB-targeting regulatory network even further. Among various 
modulators of the ErbB signalling network tetraspanins occupy a unique spot 
as effectors that target both the receptors and ligands (Fig.1). Below we 
focused on tetraspanins whose involvement in ErbB-centred signalling 
networks was clearly established.          
   
Tetraspanins and ErbB receptors. 
Recruitment of ErbB proteins to complexes with tetraspanins is known to alter 
basal and ligand-induced dimerization of the receptors, their endocytic 
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trafficking and signal transduction, thus suggesting a regulatory role for 
tetraspanins.  
CD9 and ErbB receptors. CD9 can be co-immunoprecipitated with EGFR and 
β1 integrins from various cancer cell lines (7-9) . A steady-state level of EGFR 
was negatively regulated by CD9, and antibody-induced ligation of CD9 
facilitated ligand-induced endocytosis of the receptor (7; 10). The surface 
clearance of EGFR was linked to CD9-dependent regulation of the expression 
of dynamin-2, a critical component of various endocytic pathways (10). 
Ligand-induced phosphorylation of EGFR and its partner adaptor protein Shc 
was decreased in CD9-expressing cells when compared to control, and CD9 
was also shown to attenuate EGFR-induced activation of PI3-kinase and 
MAPK/Erk pathways (7; 11).       
CD82 and ErbB receptors. Data generated in various laboratories strongly 
support the notion that CD82 acts as a negative regulator of EGFR signalling. 
We have initially reported that CD82 can be co-immunoprecipitated with 
EGFR, ErbB3 and ErbB2 (12; 13). An increase in the expression of CD82 in 
mammary epithelial cells did not affect ligand binding to EGFR but attenuated 
ligand-induced homodimerization of the receptor and EGFR-ErbB2 
heterodimerization. This effect on dimerization was specific for EGFR-
containing dimers as ErbB2-ErbB3 dimers were not affected (13). CD82 also 
accelerated ligand-induced internalization of EGFR and affected the kinetics 
of EGFR-triggered phosphorylation of downstream cellular targets. Danglot 
and colleagues used a cervical carcinoma cell line to examine effects of CD82 
knockdown on internalization and activation of EGFR (14). In this study CD82 
depletion restrained receptor diffusion and allowed more efficient recruitment 
of AP-2 adaptor to the EGF-activated receptor thus facilitating clathrin-
mediated endocytosis of EGFR. They also found that the basal surface level 
of EGFR was decreased in CD82-depleted cells. Thus, both of these studies 
demonstrated that the expression level of CD82 may be an important factor 
that controls cell-type specific endocytic trafficking and signaling via EGFR.  
Variations in the composition of CD82-centred microdomains may contribute 
further to cell type specific modifications of the endocytic machinery involved 
in the internalization of activated EGFR. In this regard, we have demonstrated 
that there is a correlation between CD82 expression level and levels of a-
series gangliosides (15), glycosphingolipids that are known to control various 
aspects of signalling via ErbB receptors (16-19). Furthermore, we have shown 
that the stability of CD82-EGFR interactions is dependent on gangliosides. 
Specifically, pharmacological depletion of gangliosides or sialidase-dependent 
changes in ganglioside profile in CD82-expressing cells resulted in weakening 
of CD82-EGFR interactions and in reduction of EGFR phosphorylation in 
response to EGF (15). Interestingly, interactions of CD9 with EGFR were not 
affected in these experiments indicating dissimilarities between different 
tetraspanin-EGFR complexes. Wang and colleagues demonstrated that the 
inhibition of EGFR signaling through tetraspanin CD82 and ganglioside GM3 
required PKC-α translocation to the plasma membrane and phosphorylation 
of EGFRThr654 (20). In the study GM3, which belongs to a-series gangliosides, 
facilitated the association of EGFR with caveolin-1, CD82 and PKC-α. These 
authors found that CD82 was critical for the recruitment of PKC-α into the 
complex and activation of the enzyme. More recently, we demonstrated that 
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PKC-α recruitment to tetraspanin-enriched microdomains, and its activation 
by HSPG affected interactions of EGFR with c-Cbl, a principal E3 ubiquitin 
ligase responsible for the ligand-induced ubiquitylation of the receptor (21). 
Importantly, ubiquitylation of EGFR by EGF ligands containing a heparin 
binding domain was attenuated in the presence of CD82. We also found that 
postendocytic trafficking of EGFR was diversified in the presence of CD82. 
The involvement of CD82 in the regulation of EGFR was also suggested in a 
recent study of non-small cell lung cancers (NSCLC). Analysis of NSCLC cell 
lines and samples from the patients indicated that activating mutations in 
EGFR are directly linked to downregulation of CD82. Whilst not investigated 
at the molecular level, the underlying mechanisms were proposed to involve 
EGFR-dependent release of CD82 via exosomes (22).  
CD151 and ErbB receptors. Tetraspanin CD151 forms stoichiometric 
complexes with laminin-binding integrins (i.e. α3β1, α6β1/β4, α7β1), and most 
CD151-dependent cellular phenomena can be explained by CD151-integrin 
interactions. In earlier studies depletion of CD151 from breast cancer cells 
attenuated EGF-induced phosphorylation of FAK, Erk1/2 and β4 integrin 
subunit (23). Furthermore, ErbB2-driven tumourigenesis and metastasis was 
suppressed in animals lacking CD151 (24). These authors also reported that 
the inhibitory effect of ErbB2-targeting therapeutics (Herceptin and lapatinib) 
was accentuated in CD151-depleted cells plated on laminins (23). By 
contrast, we found that the growth suppressive effect of Herceptin was 
negligible when CD151-depleted cells were placed in laminin-rich extracellular 
matrix (25). In this experimental setting CD151 increased homodimerisation of 
ErbB2 via mechanisms involving integrin-dependent activation of RhoA 
GTPase (25). It is likely that CD151 affects ErbB signalling indirectly, as in 
neither of these studies was a physical association between CD151 and ErbB 
proteins observed.  
CD81 and ErbB receptors. Functional links between CD81 and EGFR were 
studied in the context of hepatitis C virus (HCV) infection. HCV binding and 
crosslinking with anti-CD81 mAb induced phosphorylation of EGFR and co-
internalisation of the receptor and tetraspanin into EEA-1 – positive 
endosomes (26). These results suggested that EGFR activation is required for 
HCV entry at a step occurring soon after CD81 and/or CLDN1 binding. 
Furthermore, although the authors were unable to detect CD81-EGFR 
association in co-immunoprecipitation experiments, they proposed that HCV-
induced CD81 crosslinking induced ligand-independent dimerization and 
activation of the receptor. More recently, it was reported that CD81 also plays 
a role in activation of Raf-1, a well-established down-stream target in EGFR-
dependent HCV entry. Basal phosphorylation of Raf-1 on   Ser259 and 
Ser338 could be modulated by clustering with anti-CD81 mAb (27). Given that 
phosphorylation of these residues has an opposing effect on Raf-1 activation, 
CD81 is likely to function as a key switch that controls the dynamics of the 
kinase activity during HCV infection.  
 
Tetraspanins and ErbB ligands.  
Interaction of ErbB ligands with tetraspanins. Transmembrane (tm) forms of 
HB-EGF and TGFα were identified as partners for CD9 (28; 29). Whilst it is 
unlikely that the interaction is direct (see also below), it has been shown that 
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CD9 regulates HB-EGF – and TGFα–induced juxtacrine activation of EGFR 
(29; 30). Furthermore, CD9-dependent potentiation of tm-TGFα juxtacrine 
function may be due to changed surface distribution of the protein (31).       
Proteolytic shedding. All EGF-like ligands for ErbB receptors are synthesized 
as transmembrane precursor proteins and subsequently cleaved/shed by 
ADAM17 and ADAM10, transmembrane metalloproteases of the ADAM 
superfamily (32). ADAM17 was shown to directly interact with the LEL CD9 
(33). Although the role of CD9 in modulation of the enzyme activity towards 
EGF ligands has not been investigated other studies demonstrated that 
cleavage of three of its other substrates was negatively regulated by the 
tetraspanin. ADAM10 was reported to be the main sheddase for betacellulin 
and EGF (34). In the initial report describing the ADAM10-tetraspanin 
interactions, antibodies to CD9, CD81 and CD82 were shown to increase 
shedding of EGF (35). Subsequent studies demonstrated that ADAM10 is 
recruited to tetraspanin enriched microdomains via TspanC8 tetraspanins 
which regulate various aspects of ADAM10 intracellular trafficking and control 
activity of the enzyme towards its multiple substrates (36-38). 
 
Future directions. 
ErbB proteins and their ligands are released by cells via exosomes, 
extracellular vesicles (30-100nM) secreted by all cell types (39). Importantly, 
exosome-associated ErbB ligands are more potent in stimulating proliferative 
and migratory cellular responses (40). Several tetraspanins are known to 
control production and composition of exosomes (41), and, therefore, they are 
expected to play an important role in exosome-dependent activation of ErbB 
receptors.    
The involvement of tetraspanins in proteolytic shedding of surface proteins of 
the ErbB signalling network will undoubtedly gain further momentum in the 
future. Tetraspanins are associated with ADAM proteases and other 
metalloproteinases (e.g. MT1-MMP and MMP7) (42). Not only do these 
proteases target various ErbB ligands, but they are also responsible for the 
proteolytic cleavage of ErbB receptors themselves (43; 44). For example, 
shedding of ErbB2 by ADAM10 is proposed to be one of the mechanisms of 
resistance to Herceptin/Trastuzumab-based therapies in patients with breast 
cancer (43). Thus, TspanC8-dependent regulation of the activity of ADAM10 
towards ErbB2 can be predicted. There is also an intriguing possibility that 
TspanC8 activity towards ADAM10 is further regulated by other tetraspanins. 
It has been reported that CD63 binds TIMP1, a well-established inhibitor of 
ADAM proteases (45). This lends a possibility for a spatial, tetraspanin-
dependent control over activation of ADAM proteins which may represent an 
important step in one of the recently described "bypass" signaling pathways 
involving ErbB-centred signalling network (46). 
Tetraspanins and ErbB proteins are engaged in N-linked glycans – mediated   
interactions with gangliosides which control various aspects of ErbB-
dependent signalling. Given that tetraspanins are able to modify a 
glycosylation pattern of the associated receptors (47) and cellular levels of 
gangliosides (13), it is likely that saccharide-mediated interactions could be 
one of the important factors in fine tuning of signalling via ErbB proteins. 
Thus, detailed characterisation of tetraspanin-dependent changes in ErbB 
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glycotopes will lead to better and more complete understanding of how 
tetraspanins regulate ErbB-dependent signalling networks.  
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